Literature DB >> 22035702

Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.

Edmund J Bini1, Steven Kritz, Lawrence S Brown, Jim Robinson, Donald Calsyn, Don Alderson, Kathlene Tracy, Patrick McAuliffe, Cheryl Smith, John Rotrosen.   

Abstract

Although substance abuse treatment programs are important contact points for providing health services for hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, availability of services in these programs has not been well characterized. This study evaluated the spectrum of HBV and HCV services offered by substance abuse treatment programs within the National Drug Abuse Treatment Clinical Trials Network. Our survey of substance abuse treatment program administrators covered availability of testing for HBV and HCV; hepatitis A virus (HAV) and HBV immunization; and HCV medical and nonmedical services. There were also questions covering clarity of guidelines for HBV and HCV testing and HAV and HBV immunization. Differences between methadone and nonmethadone programs were examined. Despite the importance of substance abuse in sustaining the hepatitis epidemics, few programs offer comprehensive HBV and HCV testing or HCV health care services. Interventions to improve access to hepatitis services for substance-abusing patients are needed.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22035702      PMCID: PMC3272317          DOI: 10.1016/j.jsat.2011.09.007

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  45 in total

Review 1.  National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

Authors: 
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 2.  Prevention of hepatitis A with the hepatitis A vaccine.

Authors:  Allen S Craig; William Schaffner
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

3.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

Review 4.  Global burden of disease (GBD) for hepatitis C.

Authors: 
Journal:  J Clin Pharmacol       Date:  2004-01       Impact factor: 3.126

5.  Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy.

Authors:  Gianluca Quaglio; Fabio Lugoboni; Benedetta Pajusco; Maddalena Sarti; Giorgio Talamini; Alessandro Lechi; Paolo Mezzelani; Don C Des Jarlais
Journal:  Clin Infect Dis       Date:  2003-06-24       Impact factor: 9.079

6.  Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS).

Authors:  Robert L Hubbard; S Gail Craddock; Jill Anderson
Journal:  J Subst Abuse Treat       Date:  2003-10

Review 7.  HAV infection in chronic liver disease: a rationale for vaccination.

Authors:  Piero L Almasio; Pietro Amoroso
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

Review 8.  Viral hepatitis B.

Authors:  Ching Lung Lai; Vlad Ratziu; Man-Fung Yuen; Thierry Poynard
Journal:  Lancet       Date:  2003-12-20       Impact factor: 79.321

Review 9.  Review article: hepatitis vaccination in patients with chronic liver disease.

Authors:  G Reiss; E B Keeffe
Journal:  Aliment Pharmacol Ther       Date:  2004-04-01       Impact factor: 8.171

10.  A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.

Authors:  Shiela M Strauss; Janetta M Astone; Don Des Jarlais; Holly Hagan
Journal:  Drug Alcohol Depend       Date:  2004-03-08       Impact factor: 4.492

View more
  10 in total

1.  Missed opportunities for hepatitis C testing in opioid treatment programs.

Authors:  Jemima A Frimpong
Journal:  Am J Public Health       Date:  2013-04-18       Impact factor: 9.308

2.  Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Lan Jiang
Journal:  Am J Public Health       Date:  2014-04-17       Impact factor: 9.308

3.  The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan.

Authors:  Marcia Russell; Mary Patricia Pauly; Charles Denton Moore; Constance Chia; Jennifer Mary Dorrell; Renee Junko Cunanan; Gayle Witt
Journal:  Drug Alcohol Depend       Date:  2013-10-12       Impact factor: 4.492

4.  Hepatitis C virus-related knowledge and willingness to receive treatment among patients on methadone maintenance.

Authors:  Marija Zeremski; Rositsa B Dimova; Roberto Zavala; Steven Kritz; Melissa Lin; Bryce D Smith; Jon E Zibbell; Andrew H Talal
Journal:  J Addict Med       Date:  2014 Jul-Aug       Impact factor: 3.702

5.  A qualitative analysis of provider barriers and solutions to HIV testing for substance users in a small, largely rural southern state.

Authors:  Patricia B Wright; Geoffrey M Curran; Katharine E Stewart; Brenda M Booth
Journal:  J Rural Health       Date:  2013-03-25       Impact factor: 4.333

Review 6.  Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.

Authors:  Marija Zeremski; Jon E Zibbell; Anthony D Martinez; Steven Kritz; Bryce D Smith; Andrew H Talal
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

7.  Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs.

Authors:  Bruce R Schackman; Jared A Leff; Devra M Barter; Madeline A DiLorenzo; Daniel J Feaster; Lisa R Metsch; Kenneth A Freedberg; Benjamin P Linas
Journal:  Addiction       Date:  2015-01       Impact factor: 7.256

8.  Willingness to Receive Treatment for Hepatitis C among Injecting Drug Users on Methadone Program: Implications for Education and Treatment.

Authors:  Zahra Alam-Mehrjerdi; Afsaneh Moradi; Fenglian Xu; Mehran Zarghami; Javad Salehi-Fadardi; Kate Dolan
Journal:  Addict Health       Date:  2016-04

9.  Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.

Authors:  Stevan A Gonzalez; Daniel S Fierer; Andrew H Talal
Journal:  Addict Disord Their Treat       Date:  2017-05-17

10.  Does the Strategy of Risk Group Testing for Hepatitis C Hit the Target?

Authors:  Mirjana R Jovanovic; Aleksandar Miljatovic; Laslo Puskas; Slobodan Kapor; Dijana L Puskas
Journal:  Front Pharmacol       Date:  2017-06-30       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.